Objective: We tested whether ablation methodology and study design can explain the varying outcomes in terms of atrial fibrillation (AF)-free survival at 1 year.
| INTRODUCTION
Percutaneous catheter ablation is now well established in international guidelines as an effective therapy for paroxysmal atrial fibrillation (PAF). 1, 2 However, there is a wide range of success rates (20%-100% at 12 months) 3, 4 and this is frequently attributed to technical differences in the ablation process. [5] [6] [7] No analysis has ever systematically addressed the possibility that the disparate design of trials might also contribute to the disparate results. In part, this is because the disparities are so extensive that conventional trial-by-trial analysis is unable to extract the effects.
In this analysis, we perform an arm-by-arm meta-regression in which the multi-level heterogeneity becomes a strength rather than a weakness. Treating the individual arms (with their design and corresponding outcome) as the unit of analysis, we quantify
• whether adjunctive ablation strategies such as complex fractionated atrial electrograms (CFAE), ganglionated plexi (GP) ablation, or additional lines might be additive to pulmonary vein isolation (PVI) in improving the success rate of PAF ablation;
• whether different methods of producing PVI (eg, cryoablation vs ostial radiofrequency [RF] vs wide area RF) give rise to differing success rates;
• whether any of these strategies lead to reduction in RF time or procedure time; and
• whether studies with different characteristics (eg, longer vs shorter blanking periods, different methods of atrial fibrillation
[AF] detection) would alter success rates.
The last point alludes to the possibility that factors that have nothing to do with technique have the potential to influence study outcomes. In AF ablation trials, the "success" of a study is usually quoted as the recurrence-free survival at 6 to 12 months. How such a recurrence is defined is as variable as the techniques used in these studies with variable definitions of recurrence (AF vs AF plus atrial tachycardia [AT]), 8, 9 durations of blanking period, 8, 10 and the means by which recurrence is detected (eg, using periodic Holter monitoring vs using a long-term implantable-loop recorder to detect recurrence). 8, 11 Whether such methodological details are important in defining outcomes is vital to put the results of ablation studies into context. Figure 1 ).
| MATERIALS AND METHODS

| Search strategy and data extraction
| Outcome selection
The primary outcome was the percentage of patients free from AF in each study arm. In most cases, the 12-month timepoint was chosen.
Where this was not available, the nearest available timepoint was selected. The 12-month timepoint was chosen as it was commonly available in almost all studies and was felt to be a clinically relevant timepoint by which the majority of recurrences would have been expected to occur.
| Data analysis and synthesis
Where possible, continuous variables were reported as mean ± standard deviation and categorical variables as proportions (%). A funnel plot (Supporting Information Figure 1) 
F I G U R E 2
The effect of adjunctive strategies in addition to PVI on AF-free survival. None of the adjunctive strategies resulted in significant improvements over the basic PVI lesion set. Routine use of antiarrhythmic drugs class I/III postablation came closest to reaching significance P = 0.07 with a trend toward greater success. CFAE, complex fractionated atrial electrograms; GP, ganglionated plexi; PVI, pulmonary vein isolation | 1473
The effect of PVI methodology on arrhythmia-free survival. The success of PVI is independent of the specific methodologies available to achieve it. HIFU, high-intensity focal ultrasound; PVI, pulmonary vein isolation; RF, radiofrequency; WACA, wide area circumferential ablation 
| The success of PVI is independent of the ablation methodology
There are different methodologies for performing PVI. We compared seven different methods (WACA, cryoballoon, single-shot RF, laser balloon, force-sensing, HIFU, and robot) in this meta-regression to basic ablation, which was defined as antral PVI using radiofrequency (RF), that is, absence of the other techniques included in the meta-regression ( Figure 3 ). WACA was not associated with a significantly different outcome in comparison to antral RF ablation (95% CI, −3.3%-12%; P = 0.267).
Similarly, none of the other six methodologies studied (cryoballoon, single-shot RF, laser balloon, force-sensing, HIFU, and robotic navigation) were associated with a better outcome ( Figure 3) . Together, the results presented in Figures 2 and 3 indicate that, among the paroxysmal AF techniques, the effectiveness of PVI is not enhanced by the use of any adjunctive techniques nor by the specific approaches used to achieve it.
F I G U R E 5
The effect of patient characteristics on arrhythmia-free survival. Each hypertensive patient recruited had a 24.4% greater chance of recurrence. Male sex conferred greater success. Age and LA diameter did not affect success. AF, atrial fibrillation; LA, left atrium
The effect of follow-up protocols on arrhythmia-free survival. By 12 months, the duration of a blanking period had little impact on AF-free survival (unlike results at 6 months -see text). Utilization of telemonitoring and ILR also significantly reduced AF-free survival. AF, atrial fibrillation; AT included, whether atrial tachycardia, as well as AF recurrences, counted towards the primary outcome; drug-free, whether patients had to be off class I/III agents to be classed recurrence-free; ILR, implantable loop recorder; seconds of AF, whether number of seconds of AF required to be deemed a recurrence made a difference to the outcome FERREIRA-MARTINS ET AL. WACA has become the most widely used point-by-point method to produce PVI. Procedure time did not significantly differ from an antral approach (−0.8 minutes, 95% CI, −6.4-4.8; P = 0.784; Figure 4A and 4B, Supporting Information Table 3 ), but it was associated with significantly reduced fluoroscopy exposure (−2.08 minutes, 95% CI, −3.34 to −0.83; P < 0.001; Figure 4A and 4B, Supporting Information Table 4 ). Although statistically significant, such a difference is unlikely to be clinically relevant.
Of the single-shot technologies, only single-shot RF was associated with shorter times, both procedure time (by 63 minutes, 95% CI, −71.6
to −55.3, P < 0.001; Figure 4A and 4B) and fluoroscopy time (by 11 minutes, 95% CI, −12.9 to −9.0; P < 0.001; Figure 4A and 4B).
No other techniques were associated with a shorter procedure time. Laser balloon ablation was associated with an increased procedure time ( Figure 4A and 4B). In addition to WACA and single-shot RF, robotic navigation also reduced fluoroscopy time ( Figure 4A and 4B).
| Freedom from AF varies by the characteristics of patients enrolled
Most study arms contained a substantial proportion of patients with hypertension (mean 40.6% across all study arms). The higher the proportion of patients with hypertension, the lower the AF-free survival. The presence of hypertension in a patient reduces the chance of AF-free survival by 24% in that individual (95% CI, −48.3 to 0.5%; P = 0.046; Figure 5 ).
Gender mix also had a significant affect on outcome. Studies including more males had better outcomes. Extrapolating to the individual patient level, a male patient stands a 42.8% better chance at being AF free after 1 year as compared with a female patient postablation (95% CI, 11.5 to 74.2%; P = 0.007; Figure 5 ). Neither age nor LA dimensions had a significant impact on outcomes ( Figure 5 ).
| Impact of protocols for detecting recurrence
We tested whether success rates were associated with duration of blanking period, the inclusion of freedom from AT (rather than just AF) in the primary outcome, whether patients needed to be free from antiarrhythmic drugs to count as successful, the thoroughness of electrocardiography (ECG) monitoring methods, and how many seconds of AF were required to define recurrence.
For freedom from AF at 6 months, the blanking period was found to be a significant factor with an improvement in freedom from AF of 5.4% per month blanked (95% CI, −1.1 to 9.9%; P = 0.013; Supporting Information Figure 2 ).
By the 12-month timepoint, however, blanking period is no longer significant in affecting the outcomes of AF ablation studies ( Figure 6 ).
Thoroughness of ECG sampling in the search for AF recurrences was important throughout the follow-up period. By 12 months, trials whose protocols included frequent ECG sampling rather than Holter monitoring, reported a poorer arrhythmia-free survival, by 23% for telemonitoring (95% CI, 11.4 to 33.2%; P < 0.001) and by 21% for ILR (95% CI, 6.7 to 33.5%; P = 0.006; Figure 6 ). Finally, patient selection and the protocol for defining recurrence have a large effect on outcomes.
| DISCUSSION
| Additional lesion sets do not improve outcome compared with PVI alone
Additional ablation targets such as CFAE, 9, 25, 26 GP ablation and additional lines 9, 15, 27 were not associated with improved outcomes (Figure 2 ). Although the results of PVI are not perfect, our analysis suggests that adding these alternatives do not convincingly improve success in the ablation of paroxysmal AF.
This does not mean that these alternative targets must be irrelevant. It is possible that PVI might, through an accident of anatomy, be coincidentally ablating them too. This is particularly a possibility for GP, which may well be involved in the pathogenesis of PAF 28, 29 and be disrupted by PVI. 30 Another possible reason for the ineffectiveness of other approaches might be that they enhance arrhythmia by as much as they reduce it, leaving a neutral effect. For example, both CFAE and lines can slow conduction enough to enable macroreentrant AT circuits.
31,32
4.2 | Choice of ablation technology affects procedure and fluoroscopy time, but not success rate
We found no difference between the ablation technologies in terms of their AF-free survival. In particular, WACA 10 does not, across the data as a whole, seem to be associated with improved success, in comparison with antral ablation, at least in paroxysmal AF ablation.
Nor were any of the single-shot ablation techniques, that is, cryoballoon, single-shot RF, laser balloon and HIFU, associated with a better outcome. This is consistent with the FIRE AND ICE trial, published after our analysis was completed, which showed no difference in success between cryoballoon and WACA. 33 The fact that the FIRE AND ICE shows similar results to our analysis also adds some credibility to the methodology we use here.
Although the success rates are similar across the technologies, procedural times were notably shorter for single-shot RF (by 63 minutes), and longer with CFAE (by 61 minutes) and laser-balloon ablation (by 60 minutes). Fluoroscopy times were slightly shorter for WACA, and this probably relates to these studies being done in the modern setting of electroanatomical mapping, while some of the ostial RF studies were performed before its widespread use. In addition, fluoroscopy time was shorter with single-shot RF and robotic ablation but longer where adjunctive lesions such as CFAE and lines were performed.
Since the outcomes are similar with all these techniques, the procedure and fluoroscopy times may be useful in selecting the right technology for AF ablation if aiming for maximum efficiency with the least exposure to harmful radiation for the patient and the electrophysiology lab staff.
| Patients' characteristics alter success rates of AF ablation studies
It is now accepted that modifiable or non-modifiable risk factors can increase an individual's risk of AF development. Accumulating evidence also suggests that aggressive modification of the modifiable risk factors can also decrease the risk of PAF recurrence. 34 Our meta-regression analysis identified arterial hypertension as having a negative impact on the relative success of paroxysmal AF ablation, an effect possibly due to ongoing electrical and structural remodeling of the atria and associated electrical instability. Consistent with this finding, intensive postablation blood pressure treatment has been shown to markedly decrease the risk of AF recurrence. 34 Seemingly at odds with the fact that male gender is a recognized predisposing factor for AF development, our meta-regression showed that studies containing a high proportion of males had significantly better outcomes. This suggests that men with AF have more to gain from PVI than women. This corresponds with recent studies that reported a lower success rate and a higher complication rate among women postcatheter AF ablation. 35, 36 It has also been suggested that women are referred for catheter ablation not only less frequently but also at later stages than men, despite being more symptomatic,
having a lower quality of life, and being less tolerant of antiarrhythmic drugs. 36 The changes in outcome associated with being male (42% improvement in outcome) and hypertensive (24% reduction in success) are quoted on a per patient basis in Figure 5 . Equally relevant when looking at results of studies is to think about how this would affect the results of a study based on the percentage of patients with these characteristics recruited. For example, per 20% increase in the proportion of females versus males in a study, one can expect an 8.6% reduction in AF-free survival. Per 20% reduction in the proportion of hypertensive patients, we can expect a 4.9% improvement in the final outcome of a study arm.
| Complex effect of blanking period on outcomes
Eighty percent of the trials had blanking periods due to the good clinical rationale that transient post-procedural inflammation 37 could elicit early recurrences which were not reflective of the long-term treated state.
Unlike other parameters tested in this study, the effect of blanking period on outcomes depends on when you look. By 12 months, the blanking period makes little difference. However, earlier on in the follow-up, the blanking period can make quite a large difference. With respect to 6-month outcomes, every extra month of blanking period yielded 5.4% fewer recurrence events (Supporting Information Figure 2 ). Designing a protocol with a 3-month rather than a 1-month blanking period will raise success rates at 6 months by 10.8%, an effect that will dissipate by 12 months. This is consistent with data suggesting that blanking period recurrences are predictive of later recurrences 38 such that ignoring blanking period recurrences, particularly in months 2 and 3, is unlikely to improve success rates in the long run. So although these later blanking period recurrences may not predict further recurrence by the time 6-month outcomes are measured, by 12 months they almost certainly do.
| More thorough ECG follow-up reduces success rates
Studies use a variety of approaches to detect and define AF recurrence, ranging from a single Holter monitor to continuous monitoring with an ILR. Quite rightly, each individual trial only made comparisons between its arms of comparable design, but outcomes are often compared between trials without adjusting for, or even mentioning, differences in recurrence detection protocols.
Our data indicate that designing a study to rely on a Holter monitor rather than an ILR or telemonitoring improves the apparent success rate by around 20%. This is in stark comparison to the absence of the influence of technical factors such as the method of producing PVI or adjunctive lesion sets.
| Limitations
This is not a randomized trial, but rather a meta-regression treating each arm of published studies as a unit of analysis. It is effectively an observational study. However, it provides a solution to the practical problem that although one might suppose that these nonprocedural aspects may have some impact on outcome, as clinicians we have no FERREIRA-MARTINS ET AL.
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idea what the likely magnitudes of such outcomes will be. This study provides an understanding of these effect sizes.
In addition, we are limited by the data available to us. For example, there may be limited variation in physiological parameters such as mean LA size in this group of PAF patients limiting our ability to detect a difference in outcomes in this meta-regression. A further example is that some technologies that we have grouped together may not be completely homogeneous, such as first vs second generation cryoballoons.
We could only study variables disclosed by the authors of the manuscripts. There may be other variables that are important but were not disclosed, or not even documented. All we can tell is the apparent effect size of the nonprocedural variables that happen to have been presented are much larger than the effect size of the choice of procedure.
| CONCLUSION
The key practical finding from this analysis is that when we look at the highly varied results in outcomes of AF ablation studies, study methodology is a bigger determinant than any modifications to the technique. Clearly, performing a PVI is important but how this is done and the performance of adjunctive lesion sets are less important to the final outcome than patient characteristics and the protocol for defining AF recurrence. Adjunctive lesion sets and some methods of producing PVI add to procedure and fluoroscopy time without enhancing efficacy across the study arms assessed.
Nonprocedural aspects show much greater potential for increasing the observed success rate. Per 20% increase in the proportion of males vs females in a study, one can expect an 8.6% improvement in final AF-free survival. Per 20% reduction in the proportion of hypertensive patients, we can expect a 4.9% improvement in success.
Finally, using less thorough methods of follow-up (eg, Holter monitoring)
can result in an apparent 21%-23% improvement in success compared to more thorough methods such as ILR or telemonitoring.
